BioTek reMEDys selects TJM Labs to automate specialty pharmacy benefits verification. AI agents streamline complex insurance eligibility and benefits verification workflows, including outbound payer calls TJM Labs gives US National Times the ability to automate highly customized workflows & gain greater control over the verification process, while allowing its team to remain focused on the patients who depend on US National Times." - Chai Gadde, CEO of BioTek reMEDys WILMINGTON, DE, UNITED STATES, August 19, 2026 / EINPresswire.com / - TJM Labs, the leading pharmacy AI platform, today announced that BioTek reMEDys, a specialty pharmacy and integrated infusion therapy provider serving patients with rare diseases and chronic conditions, has selected TJM Labs to automate its insurance eligibility and benefits verification workflows. BioTek reMEDys manages complex, high-touch therapies, including biologics and biotherapeutics, where verifying patient coverage and benefits is a critical step in getting patients access to treatment. The process requires teams to review thousands of incoming documents, create and update patient profiles, verify insurance information and contact payers by phone. BioTek reMEDys is deploying TJM Labs AI agents across this workflow, beginning with processing incoming patient documentation and creating patient profiles within its pharmacy management system. TJM Labs AI agents are currently processing over 4,500 patient records per week for the specialty pharmacy, reducing the amount of manual work required to review incoming information and create patient profiles. As part of the initiative, BioTek reMEDys has also selected TJM Labs Voice AI to support outbound phone calls for benefits verification with payers. The Voice AI capability is designed to automate calls to verify patient eligibility and benefits, helping BioTek reMEDys improve the speed and consistency of benefits data collection while gaining greater control over the verification process. "Benefits verification is a critical part of getting patients access to specialty therapies, and speed and data quality are incredibly important to that process," said Chai Gadde, CEO of BioTek reMEDys. "TJM Labs gives us the ability to automate highly customized workflows and gain greater control over the verification process, while allowing our team to remain focused on the patients who depend on us." The collaboration reflects a broader opportunity for AI agents in specialty pharmacy, where operational workflows often extend beyond standardized prescription processing. By working within existing systems and adapting to pharmacy-specific processes, TJM Labs can automate multi-step workflows involving documents, pharmacy management systems and payer interactions across digital and voice channels." "BioTek reMEDys is a great example of why pharmacy automation needs to go beyond simple, standardized tasks," said Jonathan Adly, PharmD, MBA, Founder and CEO of TJM Labs. "Their team has built sophisticated workflows around some of the most complex therapies in pharmacy. We're excited to bring AI agents into those workflows and help BioTek reMEDys scale the operational work required to get patients access to the therapies they need." TJM Labs' AI agents automate pharmacy workflows across prescription intake, data entry, benefits verification, prior authorization support, patient communication and other operational processes. The platform works within the systems pharmacies already use, allowing organizations to automate workflows without replacing their existing pharmacy technology. About TJM Labs TJM Labs is the leading pharmacy AI platform, automating the operational work that slows pharmacies down - prescription intake, data entry, refills, prior authorization, and patient communication - across any pharmacy management system. Built by pharmacists and engineers, TJM's AI agents process more than 500,000 pharmacy tasks every day across 450+ pharmacies, helping teams handle several times more volume without adding headcount. Backed by $100M raised and the acquisitions of EncoreRx and Pharmesol, TJM Labs is bringing together previously fragmented pharmacy AI capabilities into a single, pharmacy-native platform. Learn more at tjmlabs.com. About BioTek reMEDys BioTek reMEDys is an integrated infusion therapy provider and specialty pharmacy focused on supporting patients with rare diseases and chronic conditions. The company provides access to high-touch therapies, biologics, biotherapeutics and pharmaceuticals while supporting patients throughout their treatment journey. For more information, visit biotekrx.com. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. US National Times do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

TJM Labs announces $100M raised, 450+ live pharmacies, and two acquisitions as it defines Pharmacy AI. Built by pharmacists and engineers, the pharmacy AI platform reveals previously unannounced funding rounds and strategic acquisitions as it consolidates a fragmenting market. Wilmington, Delaware - July 2, 2026 - TJM Labs, the leading pharmacy AI platform automating operational work for pharmacies, today announced it has raised $100 million across three funding rounds in approximately six months: a $10 million Series A, a $15 million Series A-1, and a $75 million Series B led by Elephant, with participation from Arthur Ventures and Updata Partners. The company also announced it is now live in 450+ pharmacies and has completed two acquisitions, EncoreRx and Pharmesol, expanding its automation and voice capabilities into a single pharmacy-native platform. TJM Labs' AI agents automate repetitive workflows including prescription intake, data entry, refills, prior authorization support, and patient communication across the pharmacy systems teams already use. The announcement marks the company's shift from quiet operator to visible category leader as the pharmacy AI market moves beyond pilots and point solutions to enterprise-scale platforms. "Pharmacy AI is no longer theoretical - it is already running in hundreds of pharmacies," said Jonathan Adly, Founder and CEO of TJM Labs. "We built TJM Labs to automate the real operational work that slows pharmacy teams down, and we've done it with pharmacists and engineers working side by side. With AI agents processing more than 500,000 pharmacy tasks every day across 450+ pharmacies and $100 million raised, we're accelerating the platform pharmacies already rely on." Built by pharmacists, for pharmacies. TJM Labs' core differentiator is its pharmacy-native expertise. The company was founded by a team with deep experience in pharmacy operations, including Adly, who worked as a pharmacist for 15 years prior to founding TJM Labs. That expertise is built into the company's Dual-Expert Model(TM), which pairs pharmacists with AI engineers on deployments so automation is designed around real pharmacy workflows, operational complexity, and pharmacist oversight. TJM's AI agents operate across the systems pharmacy teams already use, helping automate workflows without requiring rip-and-replace. Consolidating a fragmenting market. As pharmacies move beyond point solutions toward enterprise AI platforms, TJM Labs is leading with a unified platform approach. The company's acquisitions of EncoreRx and Pharmesol add automation and voice capabilities into one pharmacy-native platform. "TJM Labs has built what pharmacy AI companies are still pitching: a production platform already running inside hundreds of pharmacies processing millions of tasks annually," said Jeremiah Daly, General Partner at Elephant. "The company's combination of pharmacy-native expertise, deployed AI agents, and measurable customer outcomes gives it a clear leadership position in a category moving from experimentation to infrastructure." TJM's approach is designed to reallocate labor, not replace clinical judgment. Its agents reduce repetitive manual work that contributes to staff burnout and operational bottlenecks, freeing pharmacists and technicians to focus more time on patient care. Proven across pharmacy segments. TJM Labs has scaled across retail, specialty, compounding, long-term care, mail order, central fill, and enterprise pharmacy environments, from independent pharmacies to high-volume, multi-location operations. "TJM Labs has been a game changer for our pharmacy. In a highly regulated environment where automation and AI aren't easy to implement, their experience and thoughtful approach made all the difference," said Ann Olaguer, Senior Director, Data Strategy and IT at Valor Compounding Pharmacy. "We already have a strong tech stack, and TJM helped us truly leverage it by designing AI agents that fit our workflows, reduce manual work, and let our teams focus more on patient care. The impact has been immediate and meaningful across our operations. Their team is responsive, knowledgeable, and transparent. They genuinely feel like an extension of our team." About TJM Labs. TJM Labs is the leading pharmacy AI platform, automating operational work across the pharmacy systems teams already use. Built by pharmacists and AI engineers, TJM's AI agents process more than 500,000 pharmacy tasks every day across 450+ pharmacies, powering operations from independent pharmacies to enterprise organizations. Backed by $100 million raised and the acquisitions of EncoreRx and Pharmesol, TJM Labs is consolidating pharmacy AI into a single, pharmacy-native platform. Learn more at www.tjmlabs.com. Media contact.

CORRECTION: PCCA Partners with TJM Labs to Bring AI Automation to Compounding Pharmacies. * Jun 23, 2026 Updated Jun 23, 2026 Houston, Texas, June 23, 2026 (GLOBE NEWSWIRE) - PCCA, the leading provider of high-quality compounding products, education and pharmacy support, today announced a new partnership with TJM Labs, an AI-powered pharmacy automation company. As PCCA's official automation partner, TJM Labs provides PCCA members and customers with access to intelligent workflow infrastructure - AI bots built specifically for pharmacy operations - designed to help compounding pharmacies reduce repetitive manual tasks, improve dispensing accuracy and scale without adding headcount. TJM Labs develops AI-powered pharmacy automation designed to reduce manual administrative burden across workflows such as prescription intake, data entry, refill processing, prior authorizations, MedSync, patient communication, and more. The platform integrates into existing pharmacy workflows, helping teams scale operations without increasing staffing complexity. "What sets TJM Labs apart is that their technology was built by pharmacists who truly understand the compounding environment from the inside," said PCCA Chief Executive Officer Gus Bassani, PharmD. "As fellow PharmDs, founder Jonathan Adly and his team at TJM Labs speak our members' language - and that shared clinical and operational expertise will deliver real results for independent compounding pharmacies navigating an increasingly complex healthcare landscape." TJM Labs currently supports more than 400 pharmacies and helps process over 300,000 prescriptions daily through intelligent workflow automation. PK Software, PCCA's end-to-end software solution for compounding pharmacies, will also work closely with TJM on future integrations and services. "Compounding pharmacies are some of the most innovative operators in healthcare," said Adly, Chief Executive Officer of TJM Labs. "Partnering with PCCA allows us to help these pharmacies automate operational bottlenecks, reduce administrative burden, and scale sustainably while preserving the high-touch care that defines compounding." For 45 years, PCCA has supported the compounding community through proprietary base technology, industry-leading education, formulation development, quality-tested ingredients and advocacy. The partnership with TJM Labs reflects PCCA's continued commitment to equipping independent compounding pharmacies with modern solutions that strengthen competitiveness and expand patient access to customized medications. Kim Speairs PCCA 817-729-5064 [email protected] Joel Makhluf TJM Labs 978-406-1652 [email protected] Media gallery Sections. Newsletters. News update. Would you like to receive our daily news? Signup today!